文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者胃肠道出血预防的疗效与安全性:随机试验的更新系统评价与网络Meta分析

Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials.
PubMed 文献 · Intensive Care Med · 2020-08-24
一句话结论PPI与H2RA对死亡率影响相似,PPI可能轻微增加死亡不能排除(低确定性);两者均减少临床重要消化道出血,高出血风险者PPI优于H2RA。

该更新网络Meta分析纳入74项随机试验、39 569例成人重症患者,评估PPI、H2RA或硫糖铝预防胃肠道出血的疗效与安全性。与无预防相比,PPI(RR 1.03,95%可信区间0.93–1.14,中等确定性)和H2RA(RR 0.98,0.89–1.08,中等确定性)对死亡率可能几乎无影响;PPI与H2RA间死亡率可能无重要差异(RR 1.05,0.97–1.14,低确定性),但完整分析的95%可信区间未排除PPI导致死亡率重要增加的可能性。PPI(RR 0.46,0.29–0.66)和H2RA(RR 0.67,0.48–0.94)可能减少临床重要消化道出血,PPI降幅可能大于H2RA(RR 0.69,0.45–0.93),该差异在高出血风险患者中可能重要。PPI(RR 1.08,0.88–1.45,低确定性)和H2RA(RR 1.07,0.85–1.37,低确定性)对肺炎可能无重要影响。

要点

  • 与无预防相比,PPI(RR 1.03,95%可信区间0.93–1.14,中等确定性)和H2RA(RR 0.98,0.89–1.08,中等确定性)对死亡率可能几乎无影响。
  • PPI与H2RA间死亡率可能无重要差异(RR 1.05,0.97–1.14,低确定性),但完整分析95%可信区间未排除PPI导致死亡率重要增加的可能性。
  • PPI(RR 0.46,0.29–0.66)和H2RA(RR 0.67,0.48–0.94)可能减少临床重要消化道出血,PPI降幅可能大于H2RA(RR 0.69,0.45–0.93)。
  • PPI相对H2RA的更大获益在高出血风险患者中可能重要,在低出血风险患者中可能不重要。
  • PPI(RR 1.08,0.88–1.45,低确定性)和H2RA(RR 1.07,0.85–1.37,低确定性)对肺炎可能无重要影响。

适用人群与场景

  • 成人重症患者,纳入比较PPI、H2RA或硫糖铝相互之间或与安慰剂/无预防的随机对照试验。

研究设计与关键结果

  • 更新系统评价与网络Meta分析,纳入74项随机试验、39 569例成人重症患者,采用贝叶斯随机效应模型,并使用GRADE方法评估绝对效应与证据确定性。
  • 与无预防相比,PPI对死亡率RR 1.03(95%可信区间0.93–1.14,中等确定性),H2RA对死亡率RR 0.98(0.89–1.08,中等确定性),两者可能几乎无影响。
  • PPI与H2RA间死亡率RR 1.05(0.97–1.14,低确定性),完整分析的95%可信区间未排除PPI导致死亡率重要增加的可能性。
  • 与无预防相比,PPI减少临床重要消化道出血RR 0.46(0.29–0.66),H2RA RR 0.67(0.48–0.94);PPI相对H2RA的RR 0.69(0.45–0.93),降幅可能更大,该差异在高出血风险患者中可能重要,在低出血风险患者中可能不重要。
  • 与无预防相比,PPI对肺炎RR 1.08(0.88–1.45,低确定性),H2RA RR 1.07(0.85–1.37,低确定性),可能无重要影响。

证据类型、等级与局限

  • 证据类型:随机对照试验的更新系统评价与网络Meta分析,采用GRADE方法评估证据确定性。
  • 死亡率比较为中等确定性证据;PPI与H2RA间死亡率比较及肺炎比较为低确定性证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该更新网络Meta分析提示PPI与H2RA对死亡率影响可能相似,但PPI可能轻微增加死亡的可能性不能排除(低确定性证据)。
  • PPI与H2RA可能减少临床重要消化道出血,高出血风险患者中PPI相对H2RA的更大获益可能重要。
  • PPI或H2RA可能不导致肺炎重要增加,但证据确定性低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Motivated by a new randomized trial (the PEPTIC trial) that raised the issue of an increase in mortality with proton pump inhibitors (PPIs) relative to histamine-2 receptor antagonists (H2RAs), we updated our prior systematic review and network meta-analysis (NMA) addressing the impact of pharmacological gastrointestinal bleeding prophylaxis in critically ill patients.

METHODS: We searched for randomized controlled trials that examined the efficacy and safety of gastrointestinal bleeding prophylaxis with PPIs, H2RAs, or sucralfate versus one another or placebo or no prophylaxis in adult critically ill patients. We performed Bayesian random-effects NMA and conducted analyses using all PEPTIC data as well as a restricted analysis using only PEPTIC data from high compliance centers. We used the GRADE approach to quantify absolute effects and assess the certainty of evidence.

RESULTS: Seventy-four trials enrolling 39 569 patients proved eligible. Both PPIs (risk ratio (RR) 1.03, 95% credible interval 0.93 to 1.14, moderate certainty) and H2RAs (RR 0.98, 0.89 to 1.08, moderate certainty) probably have little or no impact on mortality compared with no prophylaxis. There may be no important difference between PPIs and H2RAs on mortality (RR 1.05, 0.97 to 1.14, low certainty), the 95% credible interval of the complete analysis has not excluded an important increase in mortality with PPIs. Both PPIs (RR 0.46, 0.29 to 0.66) and H2RAs (RR 0.67, 0.48 to 0.94) probably reduce clinically important gastrointestinal bleeding; the magnitude of reduction is probably greater in PPIs than H2RAs (RR 0.69, 0.45 to 0.93), and the difference may be important in higher, but not lower bleeding risk patients. PPIs (RR 1.08, 0.88 to 1.45, low certainty) and H2RAs (RR 1.07, 0.85 to 1.37, low certainty) may have no important impact on pneumonia compared with no prophylaxis.

CONCLUSION: This updated NMA confirmed that PPIs and H2RAs are most likely to have a similar effect on mortality compared to each other and compared to no prophylaxis; however, the possibility that PPIs may slightly increase mortality cannot be excluded (low certainty evidence). PPIs and H2RAs probably achieve important reductions in clinically important gastrointestinal bleeding; for higher bleeding risk patients, the greater benefit of PPIs over H2RAs may be important. PPIs or H2RAs may not result in important increases in pneumonia but the certainty of evidence is low.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Wang Y, Ge L, Ye Z, et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials. Intensive Care Med. 2020. PMID: 32833040. doi:10.1007/s00134-020-06209-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。